title: Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients.
abstract: The MYBL2 gene encodes a transcription factor implicated in cell proliferation and maturation whose amplification or overexpression has been associated with different human malignancies, suggesting that it could be implicated in tumorigenesis. We analyzed MYBL2 expression and its prognostic value in 291 patients with de novo acute myeloid leukemia (AML) and we also evaluated its association with microRNAs 29 and 30 families. MYBL2 expression in AML patients was increased relative to CD34+ cells. Moreover, MYBL2 overexpression was associated with lower expression of miR-30a (P=0.024), miR-30b (P=0.021) and miR-30c (P=0.009). Multivariate analysis showed that MYBL2 expression was an independent factor for disease-free survival (HR 3.0, 95% CI 1.5-6.0, P=0.002) and cumulative incidence of relapse (HR 2.6, 95% CI 1.2-5.6, P=0.015) in patients with an intermediate-risk karyotype. In conclusion, our data showed that MYBL2 expression analysis could be useful to define subgroups of patients with poor prognosis.
authors.affiliation: Department of Medical Pathology, Hospital Universitario La Fe, Valencia, Spain.
authors.forename: Oscar
authors.initials: O
authors.lastname: Fuster
authors.forename: Marta
authors.initials: M
authors.lastname: Llop
authors.forename: Sandra
authors.initials: S
authors.lastname: Dolz
authors.forename: Paloma
authors.initials: P
authors.lastname: García
authors.forename: Esperanza
authors.initials: E
authors.lastname: Such
authors.forename: Mariam
authors.initials: M
authors.lastname: Ibáñez
authors.forename: Irene
authors.initials: I
authors.lastname: Luna
authors.forename: Inés
authors.initials: I
authors.lastname: Gómez
authors.forename: María
authors.initials: M
authors.lastname: López
authors.forename: José
authors.initials: J
authors.lastname: Cervera
authors.forename: Pau
authors.initials: P
authors.lastname: Montesinos
authors.forename: Federico
authors.initials: F
authors.lastname: Moscardó
authors.forename: Lourdes
authors.initials: L
authors.lastname: Cordón
authors.forename: Pilar
authors.initials: P
authors.lastname: Solves
authors.forename: Inmaculada
authors.initials: I
authors.lastname: de Juan
authors.forename: Sarai
authors.initials: S
authors.lastname: Palanca
authors.forename: Pascual
authors.initials: P
authors.lastname: Bolufer
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Sanz
authors.forename: Eva
authors.initials: E
authors.lastname: Barragán
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018797:Cell Cycle Proteins / Q000235:genetics*; D004843:Epistasis, Genetic / Q000502:physiology; D005260:Female; D015973:Gene Expression Regulation, Leukemic / Q000235:genetics; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000401:mortality*; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D005810:Multigene Family; D011237:Predictive Value of Tests; D011379:Prognosis; D015534:Trans-Activators / Q000235:genetics*; D015854:Up-Regulation / Q000235:genetics; D055815:Young Adult
chemical_list: D018797:Cell Cycle Proteins; C546086:MIRN30b microRNA, human; C064352:MYBL2 protein, human; D035683:MicroRNAs; D015534:Trans-Activators
keywords: Acute myeloid leukemia; MYBL2; MicroRNAs; Prognostic factors